OWP Pharmaceuticals announces drug's FDA approval

NAPERVILLE - OWP Pharmaceuticals Inc. Wednesday said it has received investigational approval from the FDA for the first-ever oral suspension of atomoxetine hydrochloride, a drug often used to treat deficit hyperactivity disorder.

This FDA application represents the fifth of several oral liquid medications the company hopes to commercialize over the next several years, OWP said.

OWP is dedicated to developing and commercializing novel oral liquid formulations. Atomoxetine hydrochloride capsules were first approved in the U.S. in 2002.

"Today we are pleased to have received (investigational) authorization for our unique formulation of a drug widely used in neuroscience for patients challenged with ADHD," said Scott Boyer, founder and chief executive officer of OWP. "As with our other potential entrants, this alternative dosage form may be preferred by patients of many ages who have trouble swallowing tablets or capsules or who experience swallowing difficulties."